Related Experiment Video
Updated: Apr 19, 2026
Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
Published on: July 6, 2022
Fmr1 KO and fenobam treatment differentially impact distinct synapse populations of mouse neocortex
Gordon X Wang1, Stephen J Smith2, Philippe Mourrain3
1Center for Sleep Sciences and Medicine, Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA; Department of Molecular and Cellular Physiology, Stanford University, Stanford, CA 94305, USA.
Abstract:
Cognitive deficits in fragile X syndrome (FXS) are attributed to molecular abnormalities of the brain's vast and heterogeneous synapse populations. Unfortunately, the density of synapses coupled with their molecular heterogeneity presents formidable challenges in understanding the specific contribution of synapse changes in FXS. We demonstrate powerful new methods for the large-scale molecular analysis of individual synapses that allow quantification of numerous specific changes in synapse populations present in the cortex of a mouse model of FXS. Analysis of nearly a million individual synapses reveals distinct, quantitative changes in synaptic proteins distributed across over 6,000 pairwise metrics. Some, but not all, of these synaptic alterations are reversed by treatment with the candidate therapeutic fenobam, an mGluR5 antagonist. These patterns of widespread, but diverse synaptic protein changes in response to global perturbation suggest that FXS and its treatment must be understood as a networked system at the synapse level.
Insights
Fragile X syndrome (FXS) causes cognitive deficits due to widespread synapse changes. New methods reveal these alterations, with some reversed by fenobam treatment, highlighting a networked system at the synapse level.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Fragile X syndrome (FXS) is linked to cognitive deficits stemming from molecular abnormalities in brain synapses.
- The high density and heterogeneity of synapses pose challenges in studying FXS-related synaptic changes.
Purpose of the Study:
- To develop and apply novel methods for large-scale molecular analysis of individual synapses.
- To quantify specific synaptic protein changes in a mouse model of FXS.
Main Methods:
- Utilized advanced techniques for high-throughput molecular profiling of individual synapses.
- Analyzed nearly one million synapses from the cortex of an FXS mouse model.
- Quantified changes across over 6,000 pairwise synaptic protein metrics.
Main Results:
- Identified distinct and quantitative changes in synaptic protein composition in the FXS mouse model.
- Observed that treatment with fenobam, an mGluR5 antagonist, partially reversed some of these synaptic alterations.
- Demonstrated widespread yet diverse synaptic protein alterations in response to global perturbation.
Conclusions:
- FXS involves complex, networked alterations at the synapse level.
- Understanding and treating FXS requires a systems-level approach to synaptic biology.
- Fenobam shows potential therapeutic effects by partially normalizing synaptic changes in FXS.
More Related Videos
10:29Inducing Cre-lox Recombination in Mouse Cerebral Cortex Through In Utero Electroporation
Published on: November 17, 2017
07:43Immunohistochemical Visualization of Hippocampal Neuron Activity After Spatial Learning in a Mouse Model of Neurodevelopmental Disorders
Published on: May 12, 2015